[go: up one dir, main page]

CL2013000724A1 - Composicion acuosa de inmunoglobulina (igg) estable durante el almacenamiento que comprende una igg, histidina, cation alcalino y ph determinado; metodo para estabilizar una composicion de igg. - Google Patents

Composicion acuosa de inmunoglobulina (igg) estable durante el almacenamiento que comprende una igg, histidina, cation alcalino y ph determinado; metodo para estabilizar una composicion de igg.

Info

Publication number
CL2013000724A1
CL2013000724A1 CL2013000724A CL2013000724A CL2013000724A1 CL 2013000724 A1 CL2013000724 A1 CL 2013000724A1 CL 2013000724 A CL2013000724 A CL 2013000724A CL 2013000724 A CL2013000724 A CL 2013000724A CL 2013000724 A1 CL2013000724 A1 CL 2013000724A1
Authority
CL
Chile
Prior art keywords
igg
composition
histidine
stabilize
determined
Prior art date
Application number
CL2013000724A
Other languages
English (en)
Inventor
Wolfgang Teschner
Harald Arno Butterweck
Bernhard Kölbl
Lucia Hofbauer
Hans-Peter Schwarz
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44721088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000724(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CL2013000724A1 publication Critical patent/CL2013000724A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013000724A 2010-09-17 2013-03-15 Composicion acuosa de inmunoglobulina (igg) estable durante el almacenamiento que comprende una igg, histidina, cation alcalino y ph determinado; metodo para estabilizar una composicion de igg. CL2013000724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38420910P 2010-09-17 2010-09-17

Publications (1)

Publication Number Publication Date
CL2013000724A1 true CL2013000724A1 (es) 2014-03-21

Family

ID=44721088

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000724A CL2013000724A1 (es) 2010-09-17 2013-03-15 Composicion acuosa de inmunoglobulina (igg) estable durante el almacenamiento que comprende una igg, histidina, cation alcalino y ph determinado; metodo para estabilizar una composicion de igg.

Country Status (23)

Country Link
US (4) US20120076779A1 (es)
EP (3) EP4289445A3 (es)
JP (4) JP6055412B2 (es)
KR (1) KR101879885B1 (es)
CN (2) CN104524566B (es)
AR (3) AR083034A1 (es)
AU (2) AU2011301803A1 (es)
BR (1) BR112013006308B1 (es)
CA (2) CA2810734A1 (es)
CL (1) CL2013000724A1 (es)
CO (1) CO6660498A2 (es)
DK (1) DK2616090T3 (es)
EA (2) EA032336B1 (es)
ES (1) ES2959479T3 (es)
FI (1) FI2616090T3 (es)
IL (1) IL225093B (es)
MX (1) MX351706B (es)
MY (1) MY188828A (es)
PL (1) PL2616090T3 (es)
PT (1) PT2616090T (es)
SG (1) SG188487A1 (es)
TW (2) TWI621625B (es)
WO (2) WO2012037534A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2011034604A2 (en) * 2009-09-17 2011-03-24 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
FI2616090T3 (fi) 2010-09-17 2023-09-21 Baxalta GmbH Immunoglobuliinien stabilointi vesipitoisen histidiiniä sisältävän valmisteen avulla pH:ssa, joka on lievästi happamasta neutraaliin
SMT202000147T1 (it) 2012-09-07 2020-05-08 Coherus Biosciences Inc Formulazioni acquose stabili di adalimumab
EP3552624A1 (en) * 2013-05-06 2019-10-16 Baxalta Incorporated Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
EP3177317B1 (en) 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
UA123496C2 (uk) * 2014-12-19 2021-04-14 Прометік Байо Терап'Ютікс, Інк. Фармацевтична композиція, що містить плазміноген, та її застосування
CN104826117B (zh) * 2015-05-05 2017-11-14 广东卫伦生物制药有限公司 用于人体血清免疫球蛋白溶液制剂的储存稳定剂
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
MX2018008300A (es) * 2016-01-13 2018-09-21 Genmab As Formulacion para anticuerpo y conjugado de farmaco del mismo.
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
WO2018079570A1 (ja) * 2016-10-26 2018-05-03 アステラス製薬株式会社 安定な医薬組成物
ES2986026T3 (es) * 2017-03-31 2024-11-08 Meiji Seika Pharma Co Ltd Formulación acuosa, formulación acuosa en inyector, agente desagregante de proteínas de anticuerpos y método de desagregación de proteínas de anticuerpos
AU2019250882B2 (en) * 2018-04-12 2025-10-16 Amgen Inc. Methods for making stable protein compositions
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
IL301681A (en) * 2020-09-27 2023-05-01 Emergent Biosolutions Canada Inc Hyperimmune globulin preparations
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3310150A1 (de) 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
DE3422000A1 (de) 1984-06-14 1985-12-19 Albert Schrem Werkzeugfabrik GmbH, 7928 Giengen Druckmittelbetaetigte spannvorrichtung zum spannen von werkzeugen oder werkstuecken
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
AU5864086A (en) 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
US4786726A (en) 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
JPH04502914A (ja) * 1988-12-15 1992-05-28 セントユール，インコーポレイテッド 免疫グロブリンを可溶化するための塩基性アミノ酸の使用
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
ES2129076T5 (es) * 1993-12-27 2003-05-16 Zlb Bioplasma Ag Procedimiento para la preparacion de un concentrado de inmunoglobulina g anti-d y composicion farmaceutica que lo contiene.
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6808706B1 (en) * 1997-10-15 2004-10-26 Asaki Kasei Pharma Corporation Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
ES2185310T3 (es) 1998-01-30 2003-04-16 Rhinopharma As Agente antivirico herbario.
EP1129186B2 (de) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
ES2541470T3 (es) * 1999-02-22 2015-07-20 University Of Connecticut Formulaciones de factor VIII libres de albúmina
DK2168984T3 (da) 1999-03-25 2012-12-10 Abbott Gmbh & Co Kg Humane antistoffer, som binder humant IL-12, og fremgangsmåder til pro-duktion heraf
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
US6555391B1 (en) 2000-08-15 2003-04-29 Baxter International, Inc. Methods of conditioning an affinity resin after storage
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
US20060024346A1 (en) * 2004-07-29 2006-02-02 Brody Richard S Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds
ATE556591T1 (de) * 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
AU2003251906B2 (en) 2002-07-12 2008-12-04 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7857828B2 (en) 2003-01-30 2010-12-28 Integrated Vascular Systems, Inc. Clip applier and methods of use
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
KR101441358B1 (ko) * 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
JP4219932B2 (ja) 2003-10-01 2009-02-04 協和発酵キリン株式会社 抗体の安定化方法及び安定化された溶液状抗体製剤
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP2007522157A (ja) 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DE602006015907D1 (de) 2005-01-14 2010-09-16 Bayer Healthcare Llc Verfahren zur reinigung von factor vii
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
KR100667860B1 (ko) 2005-10-18 2007-01-11 주식회사 녹십자 고순도 사람 혈액응고 제9인자의 정제 방법
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
ES2790887T3 (es) 2006-01-04 2020-10-29 Baxalta Inc Medio de cultivo celular sin oligopéptidos
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
CN101199845B (zh) * 2006-12-14 2012-05-23 上海国健生物技术研究院 一种稳定的抗IgE人源化单抗制剂
EP2114379A2 (en) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
DK2125866T3 (da) 2007-02-28 2013-07-29 Baxter Int Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
US7598560B2 (en) 2007-03-30 2009-10-06 Kavalieros Jack T Hetero-bimos injection process for non-volatile flash memory
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
EP2977461A1 (en) 2008-11-12 2016-01-27 Baxalta Incorporated Method of producing serum-free insulin-free factor vii
CN104398471A (zh) 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102414221A (zh) 2009-03-06 2012-04-11 健泰科生物技术公司 抗体配制剂
WO2010138736A2 (en) 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US8821879B2 (en) * 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG10201504808XA (en) 2010-03-17 2015-07-30 Abbott Res Bv Anti-Nerve Growth Factor (NGF) Antibody Compositions
FI2616090T3 (fi) 2010-09-17 2023-09-21 Baxalta GmbH Immunoglobuliinien stabilointi vesipitoisen histidiiniä sisältävän valmisteen avulla pH:ssa, joka on lievästi happamasta neutraaliin

Also Published As

Publication number Publication date
EA201692397A1 (ru) 2017-08-31
KR20130099956A (ko) 2013-09-06
US20180250401A1 (en) 2018-09-06
JP2017071631A (ja) 2017-04-13
JP2013544762A (ja) 2013-12-19
EP4289445A2 (en) 2023-12-13
CO6660498A2 (es) 2013-04-30
CN104524566A (zh) 2015-04-22
US9855331B2 (en) 2018-01-02
DK2616090T3 (da) 2023-09-18
EP2616090B8 (en) 2023-10-04
AR083034A1 (es) 2013-01-30
MX351706B (es) 2017-10-25
EP2616090B1 (en) 2023-08-23
ES2959479T3 (es) 2024-02-26
BR112013006308B1 (pt) 2022-03-22
MY188828A (en) 2022-01-06
JP6055412B2 (ja) 2016-12-27
EA027353B1 (ru) 2017-07-31
MX2013003018A (es) 2013-06-28
PT2616090T (pt) 2023-10-16
JP2018203784A (ja) 2018-12-27
EP2616090A1 (en) 2013-07-24
WO2012037534A1 (en) 2012-03-22
EP2616091A1 (en) 2013-07-24
EA032336B1 (ru) 2019-05-31
FI2616090T3 (fi) 2023-09-21
TWI621625B (zh) 2018-04-21
AU2011301803A1 (en) 2013-03-21
BR112013006308A2 (pt) 2016-06-07
CN103282042A (zh) 2013-09-04
CA2810731A1 (en) 2012-03-22
JP2013544763A (ja) 2013-12-19
AR122552A2 (es) 2022-09-21
KR101879885B1 (ko) 2018-07-18
EA201390400A1 (ru) 2013-08-30
US20120076772A1 (en) 2012-03-29
AR083035A1 (es) 2013-01-30
US8795658B2 (en) 2014-08-05
US20120076779A1 (en) 2012-03-29
AU2011301807A1 (en) 2013-03-28
CA2810734A1 (en) 2012-03-22
EP4289445A3 (en) 2024-02-21
CN103282042B (zh) 2014-12-10
TW201217395A (en) 2012-05-01
PL2616090T3 (pl) 2023-12-18
IL225093B (en) 2018-05-31
CN104524566B (zh) 2018-08-07
SG188487A1 (en) 2013-05-31
US20140370000A1 (en) 2014-12-18
WO2012037530A1 (en) 2012-03-22
TW201213342A (en) 2012-04-01
AU2011301807C1 (en) 2016-02-11
AU2011301807B2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CL2013000724A1 (es) Composicion acuosa de inmunoglobulina (igg) estable durante el almacenamiento que comprende una igg, histidina, cation alcalino y ph determinado; metodo para estabilizar una composicion de igg.
CL2014002904A1 (es) Una composición geopolimérica de aluminosilicato; metodo de preparacion.
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
PL2661798T3 (pl) Sposób komunikacji, komunikacyjny system i zawierający go system magazynowania energii
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
EP3085439A4 (en) Polyacrylic acid (salt) water absorbent, and method for producing same
CL2014003370A1 (es) Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición.
CL2014001848A1 (es) Composicion herbicida que contiene bentazon-sodico, un inhibidor de als y un inhibidor de accasa; y metodo para controlar vegetacion no deseada.
CL2011002194A1 (es) Formulacion que comprende anticuerpo en un regulador de histidina-arginina ph 4.5 a 6.5; articulo de manufactura que comprende dicha formulacion; metodo para estabilizar un anticuerpo en una formulacion farmaceutica acuosa.
BR112014015294A8 (pt) método cosmétido; de referência de cor, especialmente para implementar método; sistema para implementar o metodo, pacote de software de computador para implementar o método
EP3060229A4 (en) Stable, aqueous antibody formulations
EP3091434A4 (en) Chip starting method, multi-core processor chip and storage medium
WO2013092903A3 (en) Aqueous oxidizing composition
CL2014000487A1 (es) Composicion de concentrado en suspension acuosa que comprende acido s-(+)-abscisico con o sin una citoquinina; y metodo para tratar una semilla.
CL2013002030A1 (es) Composicion para reducir el mal olor que comprende un polimero metalizado que contiene un ion metalico soluble en agua, un neutralizador de mal olor y un portador acuoso, donde la composicion comprende un ph de 5 a 10; y metodo para reducir el mal olor.
CL2013003094A1 (es) Composiciones activas de antitranspirante que comprende una sal de aluminio y una especie de cation polihidroxioxoaluminio; metodo de fabricacion de la misma; y su uso.
MY181205A (en) Reducing the deterioraton of wetted hydrophilic coatings subjected to sterilization by radiation
WO2012035468A3 (en) Foamable topical composition
CL2013001935A1 (es) Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer.
CL2013000831A1 (es) Metodo para la determinacion del contenido de alergenos de una composicion.
BRPI0905707A2 (pt) Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
CO6890112A2 (es) Suspensión acuosa concentrada que comprende una sal ácida de dodecilguanidina
CL2013002119A1 (es) Composicion insecticida que comprende un vehiculo degradable, un compuesto de amonio, una fuente de proteina, una fuente de azucar, uno o mas insecticidas y agua; proceso para aplicar la composicion.
EG26632A (en) Methods for preparing compositions comprising ammonium nitrate double salts
WO2013162933A3 (en) Active halogen antimicrobial composition and method of use